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ABBREVIATION
NCD Non-communicable disease
AIM To examine the risk, burden, and management of non-communicable diseases (NCDs)
among people with cerebral palsy (CP).
METHOD Databases (Ovid MEDLINE, Embase Ovid, CINAHL Plus) were systematically
searched up to August 2017. Data on the prevalence of risk factors for, and the burden and
management of, cardiovascular diseases, diabetes, cancers, and respiratory diseases were
extracted.
RESULTS Thirty-six studies that examined the prevalence of risk factors among people with
CP were identified. There was inconsistent evidence that people with CP had higher
prevalence of metabolic risk factors such as hypertension, hyperlipidaemia, and obesity, but
strong evidence that they participated in low levels of physical activity, compared with
people without CP. Seven studies reported on the burden of NCDs. Adults with CP had a
higher risk of NCDs, including stroke, chronic obstructive pulmonary disease, and other heart
conditions, and death due to NCDs, including cancers, chronic obstructive pulmonary
disease, stroke, and ischaemic heart disease, compared with the general population. Only
one study reported on the management of NCD, specifically the uptake of breast cancer
screening among females.
INTERPRETATION The burden of NCDs is higher among adults with CP compared with the
general population. Further research is required to determine the prevalence of metabolic risk
factors and management of NCDs among people with CP.
Cerebral palsy (CP) is a developmental disorder that
results from an injury to the developing fetal or infant
brain.1 Diagnosis of CP is typically made between 12 and
24 months using a combination of standardized motor
assessments, neuroimaging, and a medical history.2 CP is
the most common cause of childhood physical disability
with a prevalence of 1.5 to 3.8 per 1000 live births in Eur-
ope, Australia, and the USA.3–5 The causal pathway to CP
is not well understood but risk factors include low birth-
weight, placental abnormalities, birth asphyxia, neonatal
infections, emergency Caesarean delivery,6 maternal obe-
sity,7–9 and low socio-economic status.10 Recent evidence
suggests that a significant proportion of cases have a
genetic component11,12 and those with a family history of
CP have increased risk of CP.13 Regardless of the aetiol-
ogy, the hallmark features of CP are abnormal fine and
gross motor functioning.1
Substantial reductions in mortality rates among children
with CP have been observed over the past decades, with
most children expected to survive to adulthood.14–16
Increases in life expectancy have also been observed among
adolescents and adults with CP who are unable to self-
feed, and this aligns with improvements observed in the
general population.15 However, life expectancy among
adults with CP who self-feed has not improved at the same
rate as life expectancy in the general population over the
past three decades.15 The cause of this widening gap in life
expectancy between adults with CP and the general popu-
lation is not well understood. It is clear, however, that
mobility status and particularly the maintenance of inde-
pendent mobility into middle age are strongly predictive of
survival.16,17
Over the past three decades there has been a substantial
shift in disease burden worldwide from communicable to
non-communicable diseases (NCDs).18 NCDs now account
for nearly two-thirds of deaths worldwide.19 The leading
causes of death due to NCDs are cardiovascular diseases,
cancers, respiratory diseases including asthma and chronic
obstructive pulmonary disease, and diabetes. In total, these
four types of disease account for 82% of NCD deaths.20
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The underlying causes of NCDs are shared and modifi-
able risk factors: tobacco use, unhealthy diet, physical inac-
tivity, and excess intake of alcohol.19,21 These four
modifiable risk factors contribute to metabolic risk factors
for NCDs including overweight and obesity, high blood
pressure, hyperlipidaemia, and hyperglycaemia.22–26 Lead-
ing risk factors for NCDs in the UK are tobacco smoking,
high blood pressure, high body mass index (BMI), alcohol
consumption, hyperlipidaemia, and hyperglycaemia.27
However, the combination of physical inactivity, high
BMI, and unhealthy diets represents the largest overall
contributor to disease burden.28 Physical inactivity
accounts for 3.2 million deaths and overweight and obesity
accounts for 3.4 million deaths worldwide per year.29 In
2006–2007, the cost to the UK’s National Health Service
related to poor diet was estimated to be £5.8 billion, physi-
cal inactivity was £0.9 billion, smoking was £3.3 billion,
alcohol was £3.3 billion, and obesity was £5.1 billion.30 Of
importance, there is a robust interrelationship between
physical inactivity, unhealthy dietary practices, and obesity;
thus it is difficult to unravel the direction of association
between these factors, and the progression of and burden
attributed to preventable NCD.
The management of NCDs worldwide should focus on
reduction of risk factors through primary prevention.21
Primary prevention includes targeting reductions in
tobacco smoking and alcohol consumption, and promoting
healthy diets and participation in physical activity.21 A sec-
ond priority for prevention of NCDs is opportunistic
screening of adults attending primary health care facili-
ties.21 Screening of adults at risk for cardiovascular disease
followed by a multi-factorial lifestyle intervention consist-
ing of individual and group-based counselling can improve
long-term alcohol habits, as well as the adoption of a
healthy diet and physical activity.31–33 The World Health
Organization endorses total disease risk rather than risk
management of single factors, to allow early detection and
more cost-effective management of NCDs.19,34 Timely
treatment of NCDs through universally available, afford-
able, and high-quality drugs is also a priority, as it can
reduce NCD deaths and may be cost-effective by reducing
the need for more expensive treatment as disease
progresses.21
Although CP is considered a non-progressive disorder,
in that the injury to the brain does not progress with time,
adults with CP experience increases in pain, fatigue, and
chronic musculoskeletal conditions with age.35–39 At least a
quarter of adults with CP also experience declines in
mobility by the age of 40 years.40–42 It has been proposed
that a model of worsening mobility in young adulthood,
accelerated loss of muscle mass, muscle weakness and fati-
gue, progression of motor dysfunction, and reduced partic-
ipation in physical activity exists among people with CP.43
The consequence of this negative cycle of events may be
an increased risk of NCDs and multimorbidity.43,44 Addi-
tionally, people with physical and intellectual disabilities
may be less knowledgeable about modifiable risk factors
for NCDs, and therefore less likely to participate in health
screening services for these diseases.45,46
The aim of this review was to examine the risk, burden,
and management of NCDs among people with CP. The
review focused on the four leading causes of death due to
NCD: cardiovascular diseases, cancers, chronic respiratory
diseases, and diabetes.20
The specific objectives were to examine (1) the preva-
lence of risk factors for NCDs among people with CP, (2)
the burden of NCDs among people with CP, and (3) the
management of NCDs among people with CP.
METHOD
Inclusion criteria
Full reports of original research published in English that
aligned with the objectives of the review were included.
No restrictions were placed on the type of study included
in the review. Participants were people with CP of any
age, any type of CP, and any functional ability. Studies
that included people with CP as a subgroup and reported
results for people with CP separately were included.
Search strategy
All available years of the following databases were searched
from inception to August 2017: Ovid MEDLINE (1946 to
August week 1, 2017); Embase Ovid (1974 to August 11th,
2017); CINAHL Plus (Cumulative Index to Nursing and
Allied Health Literature; 1937 to August 13th, 2017). The
reference lists of eligible studies were also searched.
Search terms
The full search strategy for each database is reported in
Appendix S1 (online supporting information). Terms relat-
ing to CP (e.g. cerebral palsy, hemiplegia, spastic, ataxic),
NCDs (e.g. cardiovascular disease, diabetes, respiratory dis-
ease, cancer), modifiable and metabolic risk factors (e.g.
physical activity, smoking, blood pressure), burden (e.g. inci-
dence, prevalence, mortality), and management (e.g.
screening, treatment) were included in the search strategy.
Data collection and analysis
Titles and abstracts of search results were screened, and
studies that did not meet the inclusion criteria were
excluded. If a study seemed to meet the inclusion criteria
or if there was any doubt about the inclusion of the study,
the full text of the article was retrieved. Data were
extracted on participant characteristics (age, sex,
What this paper adds
• Adults with cerebral palsy (CP) have an increased risk of non-communicable
diseases (NCDs) and increased risk of death because of NCDs.
• Evidence is inconsistent about the elevated prevalence of metabolic risk
factors for NCDs.
• Evidence is consistent that people with CP participate in reduced physical
activity.
• Only one study reported on management of NCD among people with CP.
• Available evidence suggests people with CP are less likely to receive
preventive medicine.
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ambulatory status, presence of intellectual disability);
prevalence of risk factors among people with CP and com-
parative values in people without CP if reported; measures
of burden of NCDs among people with CP and compara-
tive values in people without CP if provided, including
prevalence, risk, and rates; measures of management of
NCDs among people with CP and comparative values in
people without CP if provided, such as prevalence or inci-
dence of screening.
RESULTS
A summary of the number of records identified in each
database is presented Table I. The search of databases
identified 116 182 records. An additional 13 records were
identified from reviewing reference lists. After removal of
duplicate records, 67 247 records were screened by title
and abstract. Of these, 67 166 records were excluded.
Seventy-nine full-text articles were obtained and reviewed.
A further two full-text articles could not be obtained
despite contacting the authors.47,48 Thirty-five reports were
excluded after review of the full-text article for the follow-
ing reasons: they were not applicable to any of the objec-
tives of the review (n=16);49–64 they did not report results
for people with CP separately where those with CP were a
subgroup of the sample (n=8);45,46,65–70 they did not
include people with CP or did not state whether people
with CP were included (n=8);71–78 they were not an origi-
nal research report (n=2);79,80 and there was a second
report of a study already included (n=1).81 Overall, 44
reports were included in the review (Fig. 1).
Risk of NCDs among people with CP
The search of the literature yielded 38 reports of risk fac-
tors for NCDs among people with CP. All were cross-sec-
tional studies. A summary of each study is presented in
Table SI (online supporting information). The number of
people with CP included in each study ranged from eight
to 1397, although most studies (n=24) included fewer than
100 people with CP. Most studies included females and
males with CP (n=37). Twenty-two studies included chil-
dren aged up to 18 years, one study included children aged
up to 19 years, one study included children aged up to
20 years, two studies included young adults aged 16 to
24 years, and 12 studies included adults aged 18 years and
above.
Metabolic risk factors
Only five studies reported the prevalence of hypertension
in people with CP. The prevalence of hypertensive blood
pressure values among adults with CP was 20.0% in Ire-
land,82 25.5% in the Netherlands,83 and 30.0% in the
USA.84 The prevalence of prehypertension and hyperten-
sion was 50% among adults with CP in the USA44 and
10.5% among children with CP in Ireland.85 Only three
studies provided comparative values in the general popula-
tion; one reported that the prevalence of hypertension was
lower among adults with CP83 and two reported that it
was higher.84,85
Four studies reported the prevalence of hyperlipidaemia
among adults with CP, but only one compared the preva-
lence with the general population. The prevalence of
hyperlipidaemia ranged from 0% to 30.9%.44,82–84 Adults
with CP had a lower prevalence of hyperlipidaemia com-
pared with the general population.86 Two studies reported
the prevalence of hyperglycaemia among adults with CP as
0% and 5.7% respectively, but neither compared this with
the prevalence in the general population.82,83
Seventeen studies conducted in 13 countries reported
the prevalence of overweight and obesity according to BMI
among people with CP. Seven of these included
adults44,82–84,86–88 and 10 included children.85,89–97 There
was large variation in the prevalence of obesity reported
(7.3%–41.4% in adults and 3.3%–18.2% in children). Only
10 studies compared the prevalence of obesity among peo-
ple with CP to the prevalence reported in the general pop-
ulation. Most studies reported that the prevalence of
obesity was lower among children and adults with
CP,82,85,87,88,90,96,97 although two reported that the preva-
lence was higher among children with CP.89,93 Two stud-
ies that directly compared the prevalence of obesity among
adults with CP with that in a reference group of people
without CP found that the prevalence of obesity was
higher among adults with CP.84,86
The prevalence of central obesity, as indicated by waist
circumference, ranged from 24% to 36.4%.82,83,86 The
only study that compared central obesity with a reference
group of people without CP found that the prevalence was
similar.86
Modifiable behavioural risk factors
A low prevalence of smoking (2%) and alcohol consump-
tion (23%) was reported among 63 females with CP in the
USA.35 However, a larger study reported that the preva-
lence of smoking among adults with CP was comparable
to the general US population (19.7% vs 20.4%).84 This
was similar to that reported among Dutch adults with CP
(20.9%).83 Approximately 49% of Dutch adults with CP
reported consuming alcohol, which was lower than the
general population.83
Twenty-two studies assessed participation in physical
activity among people with CP,35,83,94,98–116 most of which
(54.5%) only included people who walked independently
with or without a walking aid.101–108,111–114 There was
Table I: Search results obtained from each database
Database Search date
Database
date range
Number
of
records
Number of
records after
removal of
duplicates
Ovid
MEDLINE
August
13th, 2017
1946 to August
week 1, 2017
34 815 21 150
Embase
Ovid
August
13th, 2017
1974 to August
11th, 2017
74 375 44 286
CINHAL
Plus
August
13th, 2017
1937 to August
13th, 2017
6992 5964
Review 3
consistently strong evidence that people with CP partici-
pated in less physical activity and spent more time in
sedentary behaviour than people without CP throughout
the lifespan.83,94,98,101,103–105,108,109,111–113,115,116 The num-
ber of children with CP who met guidelines for time spent
in physical activity varied significantly between studies,
from 7% to 94%.94,99,102,105,107,110 Some of this variation
may be explained by the different methods used to measure
physical activity and the different guidelines that children’s
activity levels were compared with. When directly com-
pared with children having typical development, two out of
three studies reported that a lower percentage of children
with CP met guidelines.94,102,105 Similarly, fewer adults
with CP met published physical activity guidelines com-
pared with adults without CP (24.4% vs 53.7%).106
Burden of NCD among people with CP
Seven studies reporting on the burden of NCDs among
people with CP were identified (Table II): three cross-
sectional studies44,84,117 and four cohort studies.118–121
Three examined the risk of NCDs44,84,118 and four
examined the risk of death due to NCDs among people
with CP.117,119–121 Sample sizes ranged from 341 to
40 482 people with CP. All studies included females and
males; three included adults only44,84,119 and four included
adults and children.117,118,120,121
All studies reporting on the risk of NCDs found an
increased risk among adults with CP. A cohort study of
1975 adults with CP and 9875 age- and sex-matched
adults without CP from Taiwan found strong evidence
that adults with CP had an increased risk of cerebrovas-
cular disease (hazard ratio 2.17, 95% confidence interval
[CI] 1.74–2.69, p<0.001).118 Similarly, a cross-sectional
survey of adults with CP in the USA found that they had
greater odds of cerebrovascular disease, hypertension,
emphysema, asthma, and other heart conditions compared
with adults without CP (odds ratios ranged from 1.32
[95% CI 1.04–1.67] for hypertension, to 2.03 [95% CI
1.39–2.97] for emphysema).84 The prevalence of multi-
morbidity (i.e. the presence of at least two chronic condi-
tions) among adults with CP in the USA was found to be
57.8%.44
116 182 records identified through
database screening 
67 247 records after duplicates removed
67 247 records screened
by title and abstract 
67 166 irrelevant records excluded
2 records excluded because
full-text articles unavailable 
79 full-text articles 
assessed for eligibility
44 studies included in 
qualitative synthesis
35 full-text articles excluded with 
reasons:
16 not applicable to any of the 
objectives of the review
8 did not report results for people 
with CP separately
8 did not include people with CP
2 not an original research report
1 a second report of a study 
already included 
13 records identified by reviewing 
reference lists
Figure 1: Study flow diagram.
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There was mixed evidence about the risk of death due to
NCDs among adults with CP. A descriptive cross-sectional
study conducted in France found that the percentage of
deaths due to respiratory diseases was higher among adults
with CP, but the percentage of deaths due to diseases of
the circulatory system and neoplasms was lower.117 Simi-
larly, in a cohort study of 341 adults with CP in London, a
higher percentage of deaths due to respiratory diseases was
reported among young adults with CP compared with
adults without CP.119 This difference did not exist between
older adults with and without CP.119 The percentage of
deaths due to diseases of the circulatory system and neo-
plasms was similar between adults with CP and the general
population.119
In contrast, two cohort studies of over 40 000 people
with CP in the USA reported that they had an increased
risk of death due to all cancers compared with the general
population.120,121 Specifically, people with CP had
increased risk of death due to breast cancer, oesophageal
cancer, colon cancer, liver cancer, bladder cancer, and
brain cancer, but reduced risk of death due to lung can-
cer.120,121 The studies found conflicting evidence about an
increased risk of death due to cancer of the genitourinary
organs.120,121 Strauss et al.121 also reported that adults with
CP had at least a twofold increased risk of death due to
chronic obstructive pulmonary disease, ischaemic heart dis-
ease, cerebrovascular disease, and other heart diseases,
compared with the general population.
Only two studies examined differences in the burden of
NCDs according to severity of disability.44,121 Ambulatory
males with CP (i.e. Gross Motor Function Classification
System [GMFCS] levels I–III) had a higher prevalence of
diabetes compared with non-ambulatory males (i.e.
GMFCS levels IV and V) and ambulatory females with CP
had a higher prevalence of stroke compared with non-
ambulatory females.44 However, non-ambulatory adults
with CP had a higher prevalence of multimorbidity com-
pared with ambulatory adults.44 When examining causes of
death among adults with CP, Strauss et al.121 defined sev-
ere CP as ‘a condition so substantial that it is exceedingly
difficult to find an appropriate placement for the client
and/or constant care/supervision is required’. Although in
this study people with severe CP of all ages had a greater
risk of death due to chronic obstructive pulmonary disease
compared with people with non-severe CP,121 the differ-
ences in risk of death due to other NCDs were age depen-
dent.121 The risk of death due to cancers, ischaemic heart
diseases, and other heart diseases was higher among people
with severe CP up to the age of 54 years, compared with
people without severe CP of the same age, but the risk was
similar between people with and without severe CP who
were older than 54 years. The risk of death due to stroke
was higher among people with severe CP aged 0 to
34 years and older than 54 years, compared with people
without severe CP, but was similar between people with
and without severe CP aged 35 to 54 years.
Management of NCD among people with CP
One study investigated the management of NCDs among
people with CP, and included 62 females with intellectual
disability only (Table II). Only 15% of females with CP
had received a screening for breast cancer in their life.122
Moreover, females with CP were 73% (95% CI 43–87%)
less likely to have received a mammography screening
compared with females with other causes of intellectual
disability.122
DISCUSSION
In summary, people with CP are at increased risk of
NCDs, which may be a direct result of reduced participa-
tion in physical activity and screening programmes. There
is mixed evidence that people with CP have increased
prevalence of metabolic risk factors such as hyperlipi-
daemia and obesity.
This review highlights the consistent evidence that peo-
ple with CP participate in reduced levels of physical activ-
ity throughout their lifespan. The causal link between lack
of physical activity, metabolic risk factors, and NCDs sug-
gests that people with CP may be at increased risk of
NCDs as a result of chronic inactivity. Conversely, the few
studies that investigated the prevalence of metabolic risk
factors among adults with CP reported similar or lower
prevalence of risk factors compared with the general popu-
lation. These studies, however, mostly included small num-
bers of relatively young adults, and therefore potentially do
not give a representative depiction of the prevalence of
metabolic risk factors in the CP population.
While the prevalence of overweight and obesity was the
most widely reported metabolic risk factor, there was large
variation in the prevalence reported between studies. This
may partly be because studies used different methods to
classify overweight and obesity according to BMI in chil-
dren, such as the International Obesity Task Force or the
World Health Organization cut-offs.123 Additionally,
prevalence of obesity was reported across several countries,
which may explain variation. Although many studies
reported a lower prevalence of obesity among people with
CP compared with the general population, BMI is not sen-
sitive to detect excess body fat in people with CP.124
Adults with impaired mobility with high body fat may be
misclassified as normal weight, resulting in metabolic risk
factors not being identified.125 Further, height is difficult
to ascertain in people with CP, particularly among those in
GMFCS levels IV and V because of lower limb contrac-
tures and reduced standing balance, making BMI poten-
tially unfeasible to assess in the clinic. Indeed, measures of
central adiposity are better predictors of metabolic risk fac-
tors than BMI among people with CP53,82 and thus a more
accurate and feasible indicator of increased risk of NCDs.
Despite identifying an increased risk of NCDs among
adults with CP, this review also highlights the lack of epi-
demiological data on the risk of NCDs in this population
worldwide. Only two studies so far have directly compared
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the risk of NCDs between adults with and without CP. Of
these, one only investigated the risk of stroke118 and one
was a cross-sectional study using self-reported presence of
disease as the outcome.84 Similarly, only four studies have
reported the incidence of death due to NCDs among
adults with CP compared with the general population, with
conflicting results. Although two large cohort studies con-
ducted in the USA did identify an increased risk of death
due to cancers, cardiovascular diseases, and chronic respi-
ratory diseases,120,121 two smaller studies did not report a
difference in the risk of death due to NCDs between peo-
ple with and without CP.117,119 Additionally, only two
studies examined the burden of NCDs according to dis-
ability severity. These studies used different categorizations
of disability severity and therefore the results are not com-
parable. However, the results of both studies suggest that
the burden may differ according to disability severity, with
more severe disability not necessarily indicating a higher
risk of NCDs. Disability severity as a predictor of the risk
of NCDs should be examined further to aid efficient iden-
tification of adults with CP most at risk.
There is a dearth of literature on preventive medicine for
adults with CP. Only one study examined the uptake of
screening, specifically breast cancer screening, among
females with CP and found a very low rate. Children and
adults with disabilities including CP have consistently
higher health care use, including more visits to clinicians,
more prescriptions dispensed, more hospitalizations, partic-
ularly elective and medical admissions, longer length of stay,
and higher numbers of procedures per admission.55,126,127
Despite this increased use, people with disabilities report
difficulties accessing needed care.126 Over 20% of children
with CP report unmet therapy services needs,128 and adults
with CP report having inadequate access to the coordinated
services that they received as children when they experience
chronic health conditions during middle age.129 These diffi-
culties with accessing health care may contribute to the
higher incidence of NCDs in this population, which may be
prevented if metabolic risk factors such as hyperlipidaemia
were identified and treated early.21,130 Indeed, McPhee
et al.131 demonstrated that age was significantly associated
with decreased endothelial function and arterial stiffness in
CP, independent of central adiposity and mobility status.
While this review indicates that chronic physical conditions
are prevalent among people with CP, a recent review also
highlighted the high prevalence of mental health conditions
among young people with CP.132 Given an increasing
prevalence of CP, owing in part to the reduction in child-
hood mortality,15,133 there is mounting evidence for the
need to approach health care delivery for persons with CP
within the context of a life-course health development
model.134
Limitations
Although many studies investigating risk factors for NCDs
were identified, most included a small number of partici-
pants, making it difficult to generalize the findings to the
wider CP population. Additionally, many studies did not
directly compare the prevalence of risk factors between
people with and without CP. Although some studies pro-
vided information on the prevalence of risk factors in the
general population, it is possible that any differences
observed may have been due to confounding factors. Simi-
larly, three studies reporting the burden of NCD in people
with CP only reported descriptive statistics and did not
directly compare the burden between people with and
without CP adjusting for potential confounders.44,117,119
Further, at a review level, we were unable to obtain full
texts for two articles and therefore may not have included
some relevant data.
Epidemiology and surveillance programmes are a key
component to prevention of NCDs worldwide, as they
provide essential data to identify and track high-risk popu-
lations, inform targeted solutions, and monitor trends of
health across the lifespan.130 This review highlights the
need for further epidemiological research on the risk of
NCDs among adults with CP. Further research is also
required to understand current health promotion and
screening practices for people with CP worldwide. Under-
standing these areas, and the barriers people with CP expe-
rience to accessing integrated health services throughout
their lifespan, are key to identifying ways to reduce the risk
of NCDs in this population.
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